12
Participants
Start Date
June 21, 2018
Primary Completion Date
April 14, 2020
Study Completion Date
November 25, 2021
Avelumab
Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
Cabozantinib
Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
Huntsman Cancer Institute, Salt Lake City
Collaborators (1)
EMD Serono
INDUSTRY
University of Utah
OTHER